NovaBridge Biosciences announced its full-year 2025 financial results, highlighting successful transformation into a global biotech platform with two leading drug candidates: givastomig for gastric cancer and VIS-101 for wet age-related macular degeneration (wet AMD). Both drugs showed compelling proof-of-concept data, with givastomig potentially eligible for FDA Accelerated Approval and a Phase 3 trial planned for late 2026, while VIS-101 is set to begin Phase 2b studies in the second half of 2026. The company ended 2025 with $210.8 million in cash, supporting operations through 2028, and expanded its leadership team to drive future growth. This progress positions NovaBridge to advance these therapies toward commercialization and patient access.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Immuron Limited announced a 6% increase in global sales for FY26, reaching AUD$7.7 million, driven by a 10% rise in Australian sales and significant growth in Canada and the US markets. The growth in Australia is attributed to enhanced digital market...
GRAVITY Co., Ltd. has officially launched Ragnarok: The New World, an open-world MMORPG based on the popular Ragnarok IP, in Southeast Asia on July 16, 2026. The game is available on both Mobile (Google Play and Apple App Store) and PC (official webs...
Zymeworks Inc. will release its second quarter 2026 financial results after market close on August 6, 2026. The company will not hold an earnings call following the release due to its pending acquisition of Theravance Biopharma. This acquisition will...
Global Net Lease, Inc. announced it will release its financial results for the second quarter ending June 30, 2026, on August 5 after the NYSE closes. The company will hold a conference call and webcast on August 6 at 11:00 a.m. ET to discuss the res...
